VASOMUNE THERAPEUTICS INC.: federal grants and contributions: 3 agreements; $3.1M value; 1 departments; 2 programs.
Assay record ASY-CA-182FEFG0A4 · Cite as: Assay Systems, “VASOMUNE THERAPEUTICS INC.: federal grants and contributions”, https://assay-systems.com/register/ca/grants/r/vasomune-therapeutics-inc/
Vasomune is developing a novel first-in-class investigational medicine to treat patients hospitalized with severe COVID-19 disease. The phase 1 study is the first-in-human study designed to demonstrated safety and tolerability of AV-001 in heathy subjects prior to testing in severely ill patients with COVID-19 disease.
The funding provided from the IAP program is to assist innovative, early stage small-and medium-sized enterprises that are unable to access existing COVID-19 business support.
Contains information licensed under the Open Government Licence – Canada. Source: Government of Canada proactive disclosure of grants and contributions (open.canada.ca, dataset 432527ab-7aac-45b5-81d6-7597107a7013), 1,327,352 rows as published, collapsed to one agreement per agreement number (per reference number where none is given) at its latest amendment, which carries the full agreement value. Years are the agreement start year. Agreements with individuals are counted but not named.